Starpharma Holdings Limited · ASX:SPL
Starpharma — Shareholder Meeting (November 2025)
35 slides from Starpharma's shareholder meeting presentation, Nov 14, 2025
Slide 1: AGM Chair address and CEO presentation
ASX Announcement AGM Chair address and CEO presentation Melbourne, Australia; 14 November 2025: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, today provides a copy of the Chair’s
Slide 2: Chair's address to shareholders
Starpharma Holdings Limited Annual General Meeting 14 November 2025 Chair’s address to shareholders Good afternoon, fellow shareholders. Welcome to Starpharma’s 2025 Annual General Meeting. On behalf of the Board of Directors, thank you for joining us today and for your continued support of Starphar
Slide 3: Operational excellence: Advancing innovation and clinical progress
Operational excellence: Advancing innovation and clinical progress This year also marked significant progress in advancing our pipeline of internal DEP® assets. A key priority for Starpharma is expediting our radiotheranostics program into clinical development. Having completed extensive pre-clinica
Slide 4: Delivering meaningful patient outcomes with advanced dendrimer technology
ASX : SPL US OTC : SPHRY Delivering meaningful patient outcomes with advanced dendrimer technology Annual General Meeting | 14 November 2025 CEO, Cheryl Maley
Slide 5: Disclaimer and forward-looking statements
Disclaimer and forward-looking statements This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assurance that these expecta
Slide 6: Our year in review
Our year in review Reflecting on a year of important progress 3
Slide 7: Market position
Market position Driving value through innovation ASX:SPL Share price Ticker US OTC: SPHRY ~A$0.45 Share Price (~USD$0.29) Market ~A$186M Capitalisation Total ordinary 418M shares on issue Pharmaceuticals, GICS classification Biotechnology & Life Sciences 52-week range $0.082 - $0.445 Average daily ~
Slide 8: Our strategy
Our strategy Optimising shareholder returns through three key focus areas 01 02 03 Maximising DEP® Building strategic Building long-term platform value partnerships sustainability Demonstrating DEP® benefits Creating licensing Increasing revenue, by developing novel, high- opportunities for DEP® and
Slide 9: 2025 Overview
2025 Overview Key achievements and key actions to advance SPL in 2026 GOALS ACHIEVED ONGOING • License DEP® clinical asset/s • FDA advice, extensive • License DEP® clinical asset/s • Advance radio assets & build outreach, global support • Partnering for Radio Assets Maximise DEP® • Optimised radio a
Slide 10: Our pipeline
Our pipeline Unlocking value through novel asset development, strategic partnerships, and product sales Internal DEP® Pipeline Partnered DEP® Programs Target Pre- Product Research Phase I Phase II Phase III Strategy indication clinical License/co- Ovarian and DEP® SN38 colorectal Clinical results re
Slide 11: Suvir Steph
Suvir Steph Associate Director, Associate Director, Business Development Clinical Development 8 years at Starpharma 18 years at Starpharma 8
Slide 12: DEP® clinical assets
DEP® clinical assets Maximising opportunities for potential out-licensing Positive FDA Journal External Conference engagement publication expertise participation Key feedback on DEP® DEP® SN38 clinical study Significant internal and Business development SN38 pathway for results peer-reviewed and ext
Slide 13: Michael
Michael Principal Research Scientist 25 years at Starpharma 10
Slide 14: Strategic opportunity in radiopharmaceuticals
Strategic opportunity in radiopharmaceuticals Optimising the DEP® platform to enhance radiotherapies Blood Kidney Clearance 1.5 Molecular Weight (kDa) 40 30 10 25-75 150 1.0 %ID/g %ID/g 20 Tumour Retention Low High 0.5 10 Tumour Uptake (time) Fast Slow 0.0 0 mAb G2 G3 G4 G5 mAb mAb G2 G3 G4 G5 mAb B
Slide 15: DEP® HER2 radiotherapy program
DEP® HER2 radiotherapy program Advancing from preclinical to clinical in 2026 • Key driver in Market size • Progression, Opportunity DEP® HER2 radio aggressive breast & resistance, and/or therapy that offers: gastric cancers toxicities from other • To develop a novel • Rapid tumour • Combined HER2+
Slide 16: Our strategy
Our strategy Optimising shareholder returns through three key focus areas 01 02 03 Maximising DEP® Building strategic Building long-term platform value partnerships sustainability 13
Slide 17: Amanda Tony
Amanda Senior Director, Business Development & Project Lead for our New Seeds program 1.5 years at Starpharma Tony Vice President, Business Development 12 years at Starpharma 14
Slide 18: Our strategic partnerships
Our strategic partnerships Expanding opportunities for commercialisation Exclusive License Joint Venture Research and Agreement • Single asset focus Option Agreement • Limited targets, multi- • USD $25M investment • Single asset focus product by Medicxi • Deal value up to ~AUD • Deal value: up to US
Slide 19: Recent media coverage and commentary
Recent media coverage and commentary Positioning DEP® as a next-gen oncology delivery platform beyond biologics 16
Slide 20: Sammi
Sammi Senior Research Scientist & Project Manager for the Genentech program Nearly 14 years at Starpharma 17
Slide 21: Medicxi strategic partnership
Medicxi strategic partnership Encouraging progress and feedback “I am really pleased that the collaboration between Petalion and SPL has been very positive, with both teams working closely and constructively toward shared goals. A great deal of work has already been done, thanks to the strong commit
Slide 22: Star Navigator
Star Navigator Expanding access to Starpharma’s proprietary dendrimers through collaborative drug development and innovation 19
Slide 23: Star Navigator
Star Navigator Expanding access to Starpharma’s proprietary dendrimers through collaborative drug development and innovation • Launched early 2025 • Flexible partnership frameworks • Designed to streamline access • Experiment yourself or engage our experts 20
Slide 24: Our strategy
Our strategy Optimising shareholder returns through three key focus areas 01 02 03 Maximising DEP® Building strategic Building long-term platform value partnerships sustainability 21
Slide 25: Laura
Laura Regulatory Affairs Manager 11 years at Starpharma 22
Slide 26: Viraleze and VivaGel® BV
Viraleze and VivaGel® BV Increasing revenues through distribution partnerships and online sales Viraleze VivaGel® BV • Registered in more than 35 jurisdictions*, including in • Registered in 40+ jurisdictions, including in the UK, Europe, the UK, and Asia. Europe, Southeast Asia, Australia and New Z
Slide 27: Gareth
Gareth Analytical and Data Science Manager & Project Lead for Starpharma’s AI program Sammi Nearly 5 years at Starpharma Senior Research Scientist Nearly 14 years at Starpharma 24
Slide 28: AI at Starpharma
AI at Starpharma Leveraging our strengths and data to accelerate the discovery and preclinical phase of drug development Number of Basic research Combining nearly 30 years compounds of expertise in dendrimer drug development with sophisticated AI tools to 5,000 – 20,000 Drug discovery accelerate res
Slide 29: Our mission is to help patients with significant illnesses
Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. 26
Slide 30: Our DEP® strategy
Our DEP® strategy Leveraging multiple pathways to maximise shareholder returns Strategic Multinational, private equity, biotechnology partnerships (revenue from platform license - development to commercialisation, R&D services) DEP Platform Radiotheranostics, ADCs, combination therapies, non- Novel
Slide 31: Our strategy & outlook
Our strategy & outlook Focusing on strategic execution and revenue generation Three focused strategic imperatives and anticipated catalysts • Progressing radiotheranostic program to the clinic 1) Maximise DEP® • Securing license/collaboration for a DEP® asset to commercialise platform value • Conver
Slide 32: Financial position
Financial position Building long-term sustainability $14.3M cash at 30 September 2025 Annual result FY25 FY24 (excluding the $8.5M upfront licensing receipt from Genentech on 22 October 2025) Revenue $4.9M $1.7M^ Increasing revenues, with multiple revenue streams: Multiple revenue streams Loss $10.0
Slide 33: Leadership team
Leadership team Driving innovation with global expertise Cheryl Justin Dr Jeremy Dr Tony Dr Brian Dr Graham Miranda Sindy Maley Cahill Paull Eglezos Kelly Richard Heery Sowden Smith Chief Chief Chief VP, Business Director, Hufton Director, Director, Commun- Executive Financial & Scientific & Develop
Slide 34: Board of directors
Board of directors Driving innovation with global expertise Rob Cheryl David Lynda Dr Jeff Dr Thomas Maley McIntyre Cheng Davies Russell AO Chief Independent Independent Independent Basser Independent Executive Non- non-executive non- Independent non- Officer & executive director; executive non- exe
Slide 35: Thank you.
ASX : SPL US OTC : SPHRY Thank you. Investor Relations Corporate Office Investor.Relations@Starpharma.com 4 – 6 Southampton Crescent www.starpharma.com Abbotsford, Victoria 3067 Australia
Starpharma Holdings — Shareholder Meeting (November 2025) on 6ix